Trial Outcomes & Findings for Lay Health Worker Led Symptom Assessment Intervention (NCT NCT03737058)

NCT ID: NCT03737058

Last Updated: 2025-02-27

Results Overview

ESAS measures participant responses to 10 common symptoms (pain, fatigue, nausea, depression, anxiety, drowsiness, shortness of breath, appetite, sleep problems, and feeling of well-being). Participants rate the intensity of 10 symptoms, each on a 11-point scale (0 to 10); sub-scores are then summed and averaged to create a total symptom score (range: 0 to 10, with 10 corresponding to worst symptom severity).

Recruitment status

COMPLETED

Target enrollment

288 participants

Primary outcome timeframe

12 months after patient enrollment

Results posted on

2025-02-27

Participant Flow

The study was implemented with CareMore Health and the Oncology Institute of Hope and Innovation, which has 26 locations across southern California. Enrollment was conducted between November 1, 2015 and September 30, 2016. Each patient participated for 12 months or until death, whichever occurred first.

Patients were excluded from the intervention and control groups if they did not require medical oncology services.

Participant milestones

Participant milestones
Measure
Control Group
All participants in the control group received usual cancer care provided by Oncology Institute for Hope and Innovation clinics.
Intervention Group
The intervention consisted of a 12-month telephonic program in which a lay health-worker (LHW), supervised by a physician assistant, assessed patient symptoms after diagnosis using the Edmonton Symptom Assessment Scale (ESAS) Participants were then sorted into two categories: High-risk or low-risk. For high-risk patients, the LHW conducted weekly telephone screenings until the patient's risk changed or death. For low-risk patients, the intervention was conducted by the LHW on a monthly basis.
Overall Study
STARTED
102
186
Overall Study
COMPLETED
100
183
Overall Study
NOT COMPLETED
2
3

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Lay Health Worker Led Symptom Assessment Intervention

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Control Group
n=102 Participants
All participants in the control group received usual cancer care provided by Oncology Institute for Hope and Innovation clinics.
Intervention Group
n=186 Participants
The intervention consisted of a 12-month telephonic program in which a lay health-worker (LHW), supervised by a physician assistant, assessed patient symptoms after diagnosis using the Edmonton Symptom Assessment Scale (ESAS) Participants were then sorted into two categories: High-risk or low-risk. For high-risk patients, the LHW conducted weekly telephone screenings until the patient's risk changed or death. For low-risk patients, the intervention was conducted by the LHW on a monthly basis.
Total
n=288 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
>=65 years
102 Participants
n=5 Participants
186 Participants
n=7 Participants
288 Participants
n=5 Participants
Age, Continuous
79 years
STANDARD_DEVIATION 7.5 • n=5 Participants
79 years
STANDARD_DEVIATION 8.0 • n=7 Participants
79 years
STANDARD_DEVIATION 7.6 • n=5 Participants
Sex: Female, Male
Female
57 Participants
n=5 Participants
101 Participants
n=7 Participants
158 Participants
n=5 Participants
Sex: Female, Male
Male
45 Participants
n=5 Participants
85 Participants
n=7 Participants
130 Participants
n=5 Participants
Race/Ethnicity, Customized
Race/Ethnicity, No. (%) · Non-Hispanic White
49 Participants
n=5 Participants
88 Participants
n=7 Participants
137 Participants
n=5 Participants
Race/Ethnicity, Customized
Race/Ethnicity, No. (%) · Hispanic
42 Participants
n=5 Participants
83 Participants
n=7 Participants
125 Participants
n=5 Participants
Race/Ethnicity, Customized
Race/Ethnicity, No. (%) · Non-Hispanic Black
4 Participants
n=5 Participants
6 Participants
n=7 Participants
10 Participants
n=5 Participants
Race/Ethnicity, Customized
Race/Ethnicity, No. (%) · Asian Pacific Islander
4 Participants
n=5 Participants
5 Participants
n=7 Participants
9 Participants
n=5 Participants
Race/Ethnicity, Customized
Race/Ethnicity, No. (%) · Native Hawaiian/Alaskan Native/American Indian
3 Participants
n=5 Participants
4 Participants
n=7 Participants
7 Participants
n=5 Participants
Cancer Diagnosis
Thoracic
13 Participants
n=5 Participants
29 Participants
n=7 Participants
42 Participants
n=5 Participants
Cancer Diagnosis
GI
29 Participants
n=5 Participants
50 Participants
n=7 Participants
79 Participants
n=5 Participants
Cancer Diagnosis
Genitourinary
15 Participants
n=5 Participants
33 Participants
n=7 Participants
48 Participants
n=5 Participants
Cancer Diagnosis
Malignant hematologic conditions
14 Participants
n=5 Participants
18 Participants
n=7 Participants
32 Participants
n=5 Participants
Cancer Diagnosis
Breast
18 Participants
n=5 Participants
23 Participants
n=7 Participants
41 Participants
n=5 Participants
Cancer Diagnosis
Other (i.e. skin, brain, bone, soft tissues, head/neck)
13 Participants
n=5 Participants
33 Participants
n=7 Participants
46 Participants
n=5 Participants
Cancer Stage
3
47 Participants
n=5 Participants
71 Participants
n=7 Participants
118 Participants
n=5 Participants
Cancer Stage
4
55 Participants
n=5 Participants
115 Participants
n=7 Participants
170 Participants
n=5 Participants

PRIMARY outcome

Timeframe: 12 months after patient enrollment

Population: Only participants in the intervention group were invited to complete the ESAS.

ESAS measures participant responses to 10 common symptoms (pain, fatigue, nausea, depression, anxiety, drowsiness, shortness of breath, appetite, sleep problems, and feeling of well-being). Participants rate the intensity of 10 symptoms, each on a 11-point scale (0 to 10); sub-scores are then summed and averaged to create a total symptom score (range: 0 to 10, with 10 corresponding to worst symptom severity).

Outcome measures

Outcome measures
Measure
Control Group
All participants in the control group received usual cancer care provided by Oncology Institute for Hope and Innovation clinics.
Intervention Group
n=186 Participants
The intervention consisted of a 12-month telephonic program in which a lay health-worker (LHW), supervised by a physician assistant, assessed patient symptoms after diagnosis using the Edmonton Symptom Assessment Scale (ESAS) Participants were then sorted into two categories: High-risk or low-risk. For high-risk patients, the LHW conducted weekly telephone screenings until the patient's risk changed or death. For low-risk patients, the intervention was conducted by the LHW on a monthly basis.
Edmonton Symptom Assessment Scale Score (ESAS)
Symptom score at enrollment
9.6 score on a scale
Interval 0.0 to 10.0
Edmonton Symptom Assessment Scale Score (ESAS)
Symptom score after 12 months
7.2 score on a scale
Interval 0.0 to 8.0

SECONDARY outcome

Timeframe: 12 months after patient enrollment

Emergency Department use for each patient abstracted from medical claims data review for each patient at 12 months after enrollment.

Outcome measures

Outcome measures
Measure
Control Group
n=102 Participants
All participants in the control group received usual cancer care provided by Oncology Institute for Hope and Innovation clinics.
Intervention Group
n=186 Participants
The intervention consisted of a 12-month telephonic program in which a lay health-worker (LHW), supervised by a physician assistant, assessed patient symptoms after diagnosis using the Edmonton Symptom Assessment Scale (ESAS) Participants were then sorted into two categories: High-risk or low-risk. For high-risk patients, the LHW conducted weekly telephone screenings until the patient's risk changed or death. For low-risk patients, the intervention was conducted by the LHW on a monthly basis.
Incidence of Emergency Department Visits
0.92 visits per 1000 members/yr.
0.61 visits per 1000 members/yr.

SECONDARY outcome

Timeframe: 12 months after patient enrollment

Hospitalization Use for each patient will be abstracted by medical claims data review for each patient at 12 months after enrollment.

Outcome measures

Outcome measures
Measure
Control Group
n=102 Participants
All participants in the control group received usual cancer care provided by Oncology Institute for Hope and Innovation clinics.
Intervention Group
n=186 Participants
The intervention consisted of a 12-month telephonic program in which a lay health-worker (LHW), supervised by a physician assistant, assessed patient symptoms after diagnosis using the Edmonton Symptom Assessment Scale (ESAS) Participants were then sorted into two categories: High-risk or low-risk. For high-risk patients, the LHW conducted weekly telephone screenings until the patient's risk changed or death. For low-risk patients, the intervention was conducted by the LHW on a monthly basis.
Hospitalization Visits (Claims Review)
No. of Admissions
1.02 number of visits
Standard Deviation 1.44
0.72 number of visits
Standard Deviation 0.96
Hospitalization Visits (Claims Review)
No. of readmissions
0.10 number of visits
Standard Deviation 0.41
0.18 number of visits
Standard Deviation 0.47

SECONDARY outcome

Timeframe: 12 months after patient enrollment

Intensive Care Unit Visits for each patient will be abstracted by medical claims data review for each patient at 12 months after enrollment.

Outcome measures

Outcome measures
Measure
Control Group
n=102 Participants
All participants in the control group received usual cancer care provided by Oncology Institute for Hope and Innovation clinics.
Intervention Group
n=186 Participants
The intervention consisted of a 12-month telephonic program in which a lay health-worker (LHW), supervised by a physician assistant, assessed patient symptoms after diagnosis using the Edmonton Symptom Assessment Scale (ESAS) Participants were then sorted into two categories: High-risk or low-risk. For high-risk patients, the LHW conducted weekly telephone screenings until the patient's risk changed or death. For low-risk patients, the intervention was conducted by the LHW on a monthly basis.
Intensive Care Unit Visits (Claims Review)
0.66 number of visits
Standard Deviation 1.23
0.60 number of visits
Standard Deviation 1.00

SECONDARY outcome

Timeframe: 12 months after patient enrollment

Total Health Care Costs for each patient will be abstracted by medical claims data review for each patient at 12 months after enrollment.

Outcome measures

Outcome measures
Measure
Control Group
n=102 Participants
All participants in the control group received usual cancer care provided by Oncology Institute for Hope and Innovation clinics.
Intervention Group
n=186 Participants
The intervention consisted of a 12-month telephonic program in which a lay health-worker (LHW), supervised by a physician assistant, assessed patient symptoms after diagnosis using the Edmonton Symptom Assessment Scale (ESAS) Participants were then sorted into two categories: High-risk or low-risk. For high-risk patients, the LHW conducted weekly telephone screenings until the patient's risk changed or death. For low-risk patients, the intervention was conducted by the LHW on a monthly basis.
Total Health Care Costs (Claims Review)
31,946 $USD
21,266 $USD

SECONDARY outcome

Timeframe: Change in Patient Satisfaction with Care from baseline to 5 months.

Each patient will receive a satisfaction with care survey (The Consumer Assessment of Health Care Providers and Systems - General (CAHPS)) at baseline and 5 months. We will measure the change in satisfaction from calculated as the value at 5 months minus the baseline value. Scores for satisfaction were assessed using the Consumer Assessment of Healthcare Providers and Systems-General survey question #18 which measured rating of health provider, on which scores range from 0 to 10, with higher ratings correspond to higher patient satisfaction. Scores for each group are averaged at baseline and at 12 months.

Outcome measures

Outcome measures
Measure
Control Group
n=100 Participants
All participants in the control group received usual cancer care provided by Oncology Institute for Hope and Innovation clinics.
Intervention Group
n=183 Participants
The intervention consisted of a 12-month telephonic program in which a lay health-worker (LHW), supervised by a physician assistant, assessed patient symptoms after diagnosis using the Edmonton Symptom Assessment Scale (ESAS) Participants were then sorted into two categories: High-risk or low-risk. For high-risk patients, the LHW conducted weekly telephone screenings until the patient's risk changed or death. For low-risk patients, the intervention was conducted by the LHW on a monthly basis.
Change in Patient Satisfaction With Care Using the Consumer Assessment of Health Care Providers and Systems -General Survey
Baseline (diagnosis)
8.34 score on a scale
Standard Deviation 1.83
8.10 score on a scale
Standard Deviation 1.80
Change in Patient Satisfaction With Care Using the Consumer Assessment of Health Care Providers and Systems -General Survey
5-month follow-up
8.10 score on a scale
Standard Deviation 1.96
9.25 score on a scale
Standard Deviation 1.03
Change in Patient Satisfaction With Care Using the Consumer Assessment of Health Care Providers and Systems -General Survey
Change at 5-months
-0.23 score on a scale
Standard Deviation 1.88
1.15 score on a scale
Standard Deviation 1.79

Adverse Events

Control Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 29 deaths

Intervention Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 73 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Manali I Patel, MD MPH MS

Stanford University School of Medicine

Phone: 650-723-4000

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place